文献速递淋巴瘤

ETS1是北美来源成人T细胞白血病/淋巴瘤的新型转录调控因子

ETS1 is a novel transcriptional regulator of adult T-cell leukemia/lymphoma of North American descent.
PubMed 文献 · Blood Adv · 2022-01-01

研究比较北美来源与日本来源成人T细胞白血病/淋巴瘤(NA-ATLL与J-ATLL)的染色质可及性与转录组,发现ETS1基序在NA-ATLL差异开放染色质区域富集,ETS1表达在NA-ATLL细胞系与原发肿瘤样本中显著升高,敲低ETS1可抑制NA-ATLL细胞生长,且CCR4是ETS1直接转录靶点。

要点

  • ETS1基序在NA-ATLL差异开放染色质区域富集,AP1/IRF4基序在J-ATLL更开放区域富集。
  • ETS1表达在NA-ATLL细胞系与原发肿瘤样本中显著升高,敲低ETS1抑制NA-ATLL细胞生长。
  • CCR4是NA-ATLL中ETS1直接转录靶点,可在无CCR4激活突变时增强CCR4表达/活性。

核心结论

  • ETS1被鉴定为NA-ATLL中新型 dominant 致癌转录调控因子。

研究设计与样本

  • 研究采用染色质可及性与转录组联合分析,比较NA-ATLL与J-ATLL的关键转录调控因子。
  • 研究涉及NA-ATLL细胞系与原发肿瘤样本,并在9例NA-ATLL中检出4例CCR4突变。

主要发现

  • ETS1基序在NA-ATLL差异开放染色质区域富集,AP1/IRF4基序在J-ATLL更开放染色质区域富集。
  • ETS1表达在NA-ATLL细胞系与原发肿瘤样本中均显著升高。
  • 敲低ETS1导致NA-ATLL细胞生长受抑。
  • CCR4被鉴定为NA-ATLL中ETS1直接转录靶点。
  • CCR4突变在9例NA-ATLL中检出4例。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Adult T-cell leukemia/lymphoma (ATLL) is an aggressive T-cell lymphoma associated with the human T-cell lymphotropic virus type 1 virus endemic in regions including Japan, the Caribbean islands, and Latin America. Although progress has been made to understand the disease, survival outcomes with current standard therapy remain extremely poor particularly in acute ATLL, underlying the need for better understanding of its biology and identification of novel therapeutic targets. Recently, it was demonstrated that ATLL of North American-descendent patients (NA-ATLL) is both clinically and molecularly distinct from Japanese-descendent (J-ATLL), with inferior prognosis and higher incidence of epigenetic-targeting mutations compared with J-ATLL. In this study, combined chromatin accessibility and transcriptomic profiling were used to further understand the key transcriptional regulators of NA-ATLL compared with J-ATLL. The ETS1 motif was found to be enriched in chromatin regions that were differentially open in NA-ATLL, whereas the AP1/IRF4 motifs were enriched in chromatin regions more open in J-ATLL. ETS1 expression was markedly elevated in NA-ATLL in both cell line and primary tumor samples, and knockdown of ETS1 in NA-ATLL cells resulted in inhibition of cell growth. CCR4, a previously identified oncogenic factor in ATLL, was found to be a direct ETS1 transcriptional target in NA-ATLL. As such, ETS1 provides an alternate mechanism to enhance CCR4 expression/activity in NA-ATLL, even in the absence of activating CCR4 mutations (CCR4 mutations were identified in 4 of 9 NA-ATLL cases). Taken together, this study identifies ETS1 as a novel dominant oncogenic transcriptional regulator in NA-ATLL.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Luchtel RA, Zhao Y, Aggarwal RK, et al. ETS1 is a novel transcriptional regulator of adult T-cell leukemia/lymphoma of North American descent. Blood Adv. 2022. PMID: 35675522. doi:10.1182/bloodadvances.2022007725

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。